BioTuesdays
Zenabis Logo

Zenabis completes over-subscribed rights offering

Zenabis Global’s (TSX:ZENA) rights offering was over-subscribed, resulting in the issuance of a maximum of 139,086,624 common shares at a price of 15 cents each for gross proceeds of about $20.8-million. The company is...

Achillion Logo

EMA grants Achillion danicopan PRIME designation

Achillion Pharmaceuticals’ (NASDAQ:ACHN) danicopan received the European Medicines Agency’s (EMA) priority medicines, or PRIME, designation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The EMA’s...